Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Drugs of Today (Barcelona, Spain : 1998)|November 8, 2007
Nilotinib therapy in chronic myelogenous leukemiaAlfonso Quintas-Cardama, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
New agents in the treatment of chronic myelogenous leukemiaJavier Pinilla-Ibarz, Alfonso Quintas-Cardama
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemiaFabio P S Santos, Hagop Kantarjian, Jorge Cortes, et al.
Cancer|September 2, 2006
Novel approaches in the treatment of systemic mastocytosisAlfonso Quintas-Cardama, Ahmed Aribi, Jorge Cortes, et al.
Cancer|October 6, 2010
Experimental therapeutics for patients with myeloproliferative neoplasiasMeetu Agrawal, Ravin J Garg, Jorge Cortes, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Cancer|June 16, 2004
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Oncotarget|May 3, 2017
Tumorigenesis promotes Mdm4-S overexpressionVinod Pant, Connie A Larsson, Neeraj Aryal, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.
Blood|March 21, 2012
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceElias Jabbour, Jorge Cortes, Aziz Nazha, et al.
Pageof 4